
DRUG METABOLISM AND DISPOSITION



A Publication of the American Society for Pharmacology and Experimental Therapeutics BALTINORE 2001

A Simcyp Sponsored Seminar Wednesday 4th April 2007

ADME in Drug Development:
Bridging DM-PK-PD
Using Modelling and Simulation

Register free as part of attendance at our

Hands-on Workshops on "Concepts" and "Applications" of Population based *In Vitro - In Vivo* Extrapolation of ADME Properties

For more information on this and other International Workshops and Seminars please see http://www.simcyp.com/docs/workshops.htm

2nd - 3rd April 2007 Concepts Workshop 5th - 6th April 2007 Applications Workshop

Baltimore Marriott Waterfront Hotel, Baltimore, USA

The workshops will centre around practical examples demonstrating how data generated during drug discovery and pre-clinical drug development can be used to predict:

- Metabolic drug clearance (CL)
- Metabolic drug-drug interactions (DDIs)
- Gut first-pass metabolism
- Oral drug absorption including the effect of efflux transporters
- Drug distribution to different organs
- Plasma drug concentration-time profiles
- Metabolic CL and DDIs in specific populations (pediatric, ethnic groups, disease groups)

The main emphasis will be on assessing population variability and optimizing the design of clinical studies within the framework of whole body physiologically-based pharmacokinetics (WB PBPK).

Speakers in the Seminar include:

David J Greenblatt, Dept. of Pharmacol & Exptl Therapetuics, **Tufts University**

Micaela Reddy, Research Scientist, Roche, Palo Alto

Amin Rostami, Reader in Clinical Pharmacology and Drug Metabolism, **Univ Sheffield** and Director of Scientific R&D, **Simcyp Limited**

Ed LeCluyse, Chief Scientific Officer, **Cellzdirect**

David Plowchalk, Associate Research Fellow, **Pfizer**, **Groton**

Steve Toon, Executive Director, **Simcyp Limited**, **Sheffield**

Sean Ekins, Senior Vice President, Arnold Consulting Technologies LL

Joseph Polli, Section Manager, DMPK, **GlaxoSmithKline**, **RTP**

Rajesh Krishna, Head, Quantitative Clinical Pharmacology, Merck, Rahway



Take a Dip In Our Pool

LiverPool™ 5- and 10- Donor Pooled Cryopreserved Human Hepatocytes





n Vitro Technologies, the originator of cryopreserved hepatocytes, now offers LiverPoolTM (patent pending) 5- and 10- Donor Pooled Cryopreserved Human Hepatocytes for use in toxicity, apoptosis, and metabolism studies.

- Ease of use. Available in 5- and 10-donor pooled lots.
- ◆ Convenience. Increase your available research time by eliminating the need to pool individual vials.
- Cost savings. Decrease the number of vials purchased.
- Ready to use. Pooled lots fully characterized and available for immediate delivery.
- Convenient packaging. Vial contains
 5 million viable cells.

For more information regarding this, or any In Vitro Technologies product, call toll free 888-488-3232
E-mail: info@invitrotech.com
Web: www.invitrotech.com